TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: Study Comparing Etanercept With Usual DMARD Therapy in Subjects With Rheumatoid Arthritis in the Asia Pacific Region

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Diagnosis of RA~* Currently receiving an adequate dose of methotrexate (MTX) for treatment of RA~* Active RA at time of screening and baseline~Exclusion Criteria:~* Previous or current treatment with etanercept (ETN), other tumor necrosis factor-alpha inhibitors, or other biologic agents~* Concurrent treatment with a DMARD, other than MTX, at screening~* Receipt of any DMARD, other than MTX, within 3 months before screening

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 70 Years
- Healthy Volunteers: f

Study Arms:
- 1 (Type: ACTIVE_COMPARATOR): Etanercept + Methotrexate
- 2 (Type: ACTIVE_COMPARATOR): DMARD therapy Methotrexate + Sulfasalazine/Hydroxychloroquine/Leflunomide

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Study With Lidocaine 5% Medicated Plaster in Patients Suffering From Postherpetic Neuralgia

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Adult participants, male and female, with a minimum age of 50 years at screening.~* Participants who had postherpetic neuralgia (PHN) for at least 3 months after healing of a herpes zoster skin rash.~* Only for patients who had not participated in the KF10004/01 (NCT03745404) study: Pain score of at least 4, based on an 11-point numerical rating scale (NRS) (scale of 0-10), at the screening visit. The pain assessment is the participant's recall of the pain intensity since the previous week.~* Written informed consent given.~Exclusion Criteria:~* Participation in another study of investigational drugs or devices parallel to, or less than 30 days before screening, or previous participation in this study, except previous participation in the KF10004/01 study.~* Known to or suspected of not being able to comply with the study protocol.~* Any clinically significant condition that would, in the investigator's opinion, preclude study participation for instance alcohol, medication or drug dependency, neurotic personality, psychiatric illness, epilepsy or suicide risk.~* Pregnancy or nursing mother.~* Woman in childbearing age without satisfactory contraception.~* Hypersensitivity to lidocaine or amide-type local anesthetic drugs.~* Active herpes zoster lesion or dermatitis of any origin at the affected site with PHN.~* Evidence of another cause for pain in the area affected by herpes zoster in addition to PHN, such as lumbar radiculopathy, surgery or trauma, if this could confound assessment or self-evaluation of the pain due to PHN.~* Participants who had neurological ablation by block or neurosurgical intervention for control of pain in PHN.~* Participants using topically applied analgesic compounds on the PHN affected area.~* Presence of other severe pain that could confound assessment or self-evaluation of the pain due to PHN.~* Participants with severe hepatic disorder and/or alanine or aspartate aminotransferase equal to or above 3-fold the upper limit of normal (ULN).~* Participants with severe renal disorder and/or increased serum creatinine equal to or above 1.5-fold the upper limit of normal (ULN).~* Participants who are undergoing active treatment for cancer, are known to be infected with the human immunodeficiency virus (HIV), or being acutely and intensively immunosuppressed following transplantation.

- Gender: ALL
- Minimum Age: 50 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Lidocaine 5% medicated plaster (Type: EXPERIMENTAL): Up to 3 plasters were applied per day.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Examination of the Anti-inflammatory and Insulin Sensitizing Properties of Doxycycline in Humans

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Ambulatory, medically stable, able to give informed consent, and comply with the protocol.~* Obesity with BMI \>30 kg/m2.~* DM2 for less than 10 years.~* 7.5% \< HA1C \< 10%~* Taking insulin and/or oral medications (biguanide, sulfonlylurea, etc.)~Exclusion Criteria:~* Mental states that would preclude complete understanding of the protocol and compliance.~* Chronic illness such as renal failure (with creatinine clearance \<80 ml/min for Specific Aim 2).~* Women of child-bearing age because of the potential hazard to the fetus (doxycycline may cause permanent discoloration of the teeth and deposition in bone inhibiting growth) and because doxycycline may render oral contraceptives less effective.~* Nursing mothers.~* Allergy to tetracyclines.~* Subjects taking the following drugs: penicillin or it's derivatives, anticoagulant therapy, antacids containing aluminum, calcium, or magnesium, iron-containing preparations, bismuth subsalicylate, barbiturates, carbamazepine, phenytoin or methoxyflurane, thiazolidinediones (TZD)

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 60 Years
- Healthy Volunteers: t

Study Arms:
- Doxycycline (Type: EXPERIMENTAL): Participants with DM2 receiving doxycycline 100mg BID
- Placebo (Type: PLACEBO_COMPARATOR): Pills prepared identical to doxycycline.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Study of N91115 in Patients With Cystic Fibrosis Homozygous F508del-CFTR Mutation

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE1
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~1. Male or female, age ≥ 18 years with confirmed diagnosis of CF, homozygous for the F508del-CFTR mutation based on historical results generated by Ambry Genetics within the past two years or if unavailable, confirmed by testing done within the past 28 days~2. Sweat chloride ≥ 60 (milliequivalents) mEq/L, by quantitative pilocarpine iontophoresis test (QPIT) at screening~3. Weight ≥ 40 kg at screening~4. Forced expiratory volume (FEV1) ≥ 40% of predicted normal for age, gender, and height (Hankinson standards) pre- or post-bronchodilator value, at screening~5. Oxygen saturation by pulse oximetry ≥ 90% breathing ambient air, at screening~6. Hematology, clinical chemistry and urinalysis results with no clinically significant abnormalities that would interfere with the study assessments at screening~Exclusion Criteria:~1. Any acute infection, including acute upper or lower respiratory infections and pulmonary exacerbations that require treatment or hospitalization within 2 weeks of Study Day 1~2. Any change in chronic therapies for CF lung disease (e.g., Ibuprofen, Pulmozyme®, hypertonic saline, Azithromycin, Tobi®, Cayston®) within 4 weeks of Study Day 1~3. Blood hemoglobin \< 10 g/dL at screening~4. Serum albumin \< 2.5 g/dL at screening~5. Abnormal liver function defined as ≥ 3 x upper limit of normal (ULN) in 3 or more of the following: aspartate aminotransferase (AST), alanine aminotransferase (ALT), g-glutamyl transferase (GGT), alkaline phosphatase (ALP), or total bilirubin at screening~6. History of abnormal renal function (creatinine clearance \< 50 mL/min using Cockcroft-Gault equation) within a year of screening~7. History, including the screening assessment, of ventricular tachycardia or other ventricular arrhythmias~8. History, including the screening assessment, of prolonged cardiac QT interval and/or QTcF (QT with Fridericia's correction) interval (\> 450 msec)~9. History of solid organ or hematological transplantation~10. History of alcohol abuse or drug abuse (including cannabis, cocaine, and opioids) in the year prior to screening~11. Use of continuous (24 hr/day) or nocturnal supplemental oxygen

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Study Arms:
- Group 1 - 50 mg (Type: EXPERIMENTAL): Every 12 hour oral dosing of N91115 for 28 days
- Group 2 - 100 mg (Type: EXPERIMENTAL): Every 12 hour oral dosing of N91115 for 28 days
- Group 3 - 200 mg (Type: EXPERIMENTAL): Every 12 hour oral dosing of N91115 for 28 days
- Group 4 - Placebo (Type: PLACEBO_COMPARATOR): Every 12 hour oral dosing of placebo comparator for 28 days

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Open-label Study to Evaluate the Effectiveness of an Intramuscular Formulation of Aripiprazole (OPC-14597) as Maintenance Treatment in Patients With Bipolar I Disorder

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Completed participation in Trial 31-08-250~* De novo subjects not participating in Trial 31-08-250~* Subjects who are able to provide written informed consent.~* Male and female subjects 18 years of age or older at time of informed consent~* Subjects who, in the investigator's judgment, require chronic treatment with an antipsychotic medication for their bipolar I disorder and would benefit from extended treatment with a long-acting injectable formulation~* Subjects who have a recurrence of mood episode or exacerbations of mood symptoms when they are not receiving treatment for their bipolar I disorder or are noncompliant with treatment for their bipolar I disorder~* Have an outpatient status~Exclusion Criteria:~* Experienced 9 or more mood episodes within the past year~* A current manic episode with a duration of \> 2 years~* Currently meet DSM-IV-TR criteria for substance abuse or substance dependence; this includes the abuse of alcohol and benzodiazepines, but excludes the use of caffeine and/or nicotine~* Hypothyroidism or hyperthyroidism, unless condition has been stabilized~* Diagnosed with epilepsy or a history of seizures~* Known to be allergic, intolerant, or unresponsive to prior treatment with aripiprazole or other quinolinones~* Sexually active women of childbearing potential and sexually active men who will not commit to utilizing 2 of the approved birth control methods or who will not remain abstinent during this trial and for 180 days following the last dose of trial medication~* Females breastfeeding or pregnant (positive blood pregnancy test prior to receiving trial drug)~* Risk of committing suicide~* Abnormal laboratory test results, vital signs and ECG results~* Participated in any clinical trial other than Trial 250 with an investigational agent within the 30 days prior to screening~* Had electroconvulsive therapy (ECT) treatment during the current episode or within 3 months~* Subjects who have not met criteria for stabilization for 4 consecutive weeks

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- Experimental (Type: EXPERIMENTAL): Aripiprazole, Intramuscular (IM) Depot

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Effect of Paroxetine on Smokers' Cardiovascular Response to Stress - 1

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Smokes an average of at least 10 cigarettes per day during the year prior to enrollment~Exclusion Criteria:~* Interested in quitting smoking within the 3 months following enrollment~* Current unstable medical condition~* Substance abuse within the year prior to enrollment~* Current use of any medications (e.g., psychoactive medications, antihypertensives) that, in the opinion of the investigators, might interfere with study measures or that would be expected to interact with paroxetine (e.g., CYP2D6 substrates)~* Smoking cessation therapy within the 3 months prior to enrollment~* Regular use of any form of tobacco other than cigarettes~* Significant psychiatric disorders as assessed by the PRIME-MD and verified by a clinician~* History of hypersensitivity to any selective serotonin reuptake inhibitor~* Pregnancy or breastfeeding

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: t

Study Arms:
- 1 (Type: EXPERIMENTAL): Active medication for 4 weeks followed by placebo for 4 weeks
- 2 (Type: EXPERIMENTAL): Placebo for 4 weeks followed by active for 4 weeks

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Topical Ruxolitinib Evaluation in Vitiligo Study 1 (TRuE-V1)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE3
- Number of Arms: 4.0

Eligibility Criteria:
Key Inclusion Criteria:~* Clinical diagnosis of non-segmental vitiligo with depigmented area including ≥ 0.5% BSA on the face, ≥ 0.5 F-VASI, ≥ 3% BSA on nonfacial areas, ≥ 3 T-VASI, and total body vitiligo area (facial and nonfacial) not exceeding 10% BSA.~* Agree to discontinue all agents used to treat vitiligo from screening through the final safety follow-up visit. Over-the-counter preparations deemed acceptable by the investigator and camouflage makeups are permitted.~* Must be willing to take appropriate contraceptive measures to avoid pregnancy or fathering a child for the duration of study participation.~Key Exclusion Criteria:~* No pigmented hair within any of the vitiligo areas on the face.~* Other forms of vitiligo (eg, segmental) or other differential diagnosis of vitiligo or other skin depigmentation disorders (eg, piebaldism, pityriasis alba, leprosy, postinflammatory hypopigmentation, progressive macule hypomelanosis, nevus anemicus, chemical leukoderma, and tinea versicolor).~* Have used depigmentation treatments (eg, monobenzone) for past treatment of vitiligo or other pigmented areas.~* Use of protocol-defined treatments within the indicated washout period before baseline.

- Gender: ALL
- Minimum Age: 12 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Double-Blind Period: Ruxolitinib cream 1.5% BID (Type: EXPERIMENTAL): Participants applied ruxolitinib 1.5% cream twice daily (BID) for 24 weeks.
- Double-Blind Period: Vehicle cream BID (Type: PLACEBO_COMPARATOR): Participants applied matching vehicle cream BID for 24 weeks.
- Treatment-Extension Period: Ruxolitinib cream 1.5% BID (Type: EXPERIMENTAL): Participants who completed the Week 24 assessments with no safety concerns could continue into the 28-week Treatment-Extension Period. Participants who applied ruxolitinib cream 1.5% BID during the Double-Blind Period continued to apply ruxolitinib cream 1.5% BID for an additional 28 weeks in the Treatment-Extension Period.
- Treatment-Extension Period: Vehicle cream to Ruxolitinib cream 1.5% BID (Type: EXPERIMENTAL): Participants who completed the Week 24 assessments with no safety concerns could continue into the 28-week Treatment-Extension Period. Participants who applied vehicle cream BID during the Double-Blind Period applied ruxolitinib cream 1.5%m BID for 28 weeks in the Treatment-Extension Period.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Cord Blood Transfusion In Preterm Neonates (CB-TrIP)

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: COHORT
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~preterm neonates born at PMA ≤30 weeks and/or with birth weight ≤1000 g born at the delivery room of Fondazione Policlinico Universitario A. Gemelli candidate to receive one or more RBC unit transfusion.~Exclusion Criteria:~One or more of the following criteria Maternal-fetal immunization Hydrops fetalis Major congenital malformations associated or not with genetic syndromes Previous transfusions Hemorrhage at birth Congenital infections (such as infections from TORCH complex) Out-born infants The health care team deems it inappropriate to approach the infant's family for informed consent

- Gender: ALL
- Minimum Age: None
- Maximum Age: None
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Comparative Abuse Liability Among African American and White Smokers

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: OTHER
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Non-Hispanic African American or white/Caucasian,~* ≥21 years old, smoke 5-30 cigarettes per day,~* daily cigarette smoker~* smoked at current rate for at least 6 months~* interested in trying e-cigarettes and heat not burn products~* not interested in or unable/unwilling to quit cigarette smoking~* willing to complete three in-person study visits~* willing to have IV catheter placed~Exclusion Criteria:~* Interested in quitting cigarettes in the next 30 days~* use of smoking cessation pharmacotherapy in the past 30 days~* use of non-cigarette tobacco products in the past 30 days~* use of e-cigarettes \>5x in lifetime~* use of e-cigarettes ≥4 of the past 30 days~* use of heat not burn products \>5x in lifetime~* use of heat not burn products ≥4 of the past 30 days~* weight \< 110 lbs~* uncontrolled hypertension (systolic BP ≥ 180 or diastolic BP ≥ 105)~* pregnant, plans to become pregnant, or breastfeeding~* live \>10 miles from study site (Fairway CRU)~* current enrollment is a research study or program that aims to alter tobacco use

- Gender: ALL
- Minimum Age: 21 Years
- Maximum Age: None
- Healthy Volunteers: t

Study Arms:
- E-Cigarette then Heat not burn. (Type: ACTIVE_COMPARATOR): We will use a 1:1 fashion randomization to product order (combustible cigarette, e-cigarette, heat-not-burn device.
- Heat not burn then E-Cigarette (Type: ACTIVE_COMPARATOR): We will use a 1:1 fashion randomization to product order combustible cigarette, heat-not-burn device, e-cigarette.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Study of NPF-08 in Patients Who Receive Colonoscopy

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: DIAGNOSTIC
- Time Perspective: None
- Masking: SINGLE
- Phase: PHASE3
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~1. Japanese men and women aged 20 years or older at obtaining the written informed consent.~2. Patients who require colonoscopy (except for emergency colonoscopy)~3. Patients who have the ability to consent and submit the written informed consent by themselves.~Exclusion Criteria:~1. Patients who have or are suspected to have gastrointestinal obstruction.~2. Patients who have or are suspected to have intestinal perforation.~3. Patients who have or are suspected to have toxic megacolon.~4. Patients who have or are suspected to have gastric evacuation disorder (gastroparesis).~5. Patients with intestinal stenosis or high-grade constipation (stool frequency of 2 or less in a week or who have used laxative on a daily basis).~6. Patients with vomiting reflex or in whom accidental ingestion may occur.~7. Patients with a history of gastrointestinal surgery (except for appendicectomy).~8. Patients who were decided as glucose-6-phosphate dehydrogenase (G-6-PD) deficiency.~9. Patients with renal impairment (urea nitrogen: 25mg/dL or more, or creatinine: 2mg/dL or more)~10. Patients with hepatic dysfunction (total bilirubin: 3.0mg/dL or more, ALT: 100IU/L or more or AST: 100IU/L or more)~11. Patients who have undergone or require therapy due to high-grade cardiac disease (including angina pectoris or myocardial infarction)~12. Patients with high risk of arrhythmia (with a history or complications of QT prolongation, myocardial infarction, angina pectoris, cardiac failure or cardiomyopathy)~13. Patients with dehydration.~14. Patients who were diagnosed with active inflammatory bowel disease at screening period.~15. Inpatients due to the reasons other than endoscopy large bowel.~16. Patients who have undergone nutritional control using total parenteral nutrition or enteral nutrition.~17. Women who are or may be pregnant, lactating or wish to become pregnant during the trial period.~18. Patients with a history or high-risk of seizure.~19. Patients with a history of shock or hypersensitivity for the active ingredient of the investigational product.~20. Patients who have received the other investigational product within 4 months before the written informed consent or who are participating in the other clinical trials.~21. Patients in whom Investigator/Sub-Investigator decided not to be eligible for this trial.

- Gender: ALL
- Minimum Age: 20 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- NPF-08 （1-day treatment） (Type: EXPERIMENTAL): None
- NPF-08 （2-day split dose） (Type: EXPERIMENTAL): None
- Moviprep（1-day treatment） (Type: ACTIVE_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete